Innovation Financial Statements From 2010 to 2024
| IPIX Stock | USD 0 0.0001 7.69% |
Check Innovation Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Innovation Pharmaceuticals' main balance sheet or income statement drivers, such as , as well as many indicators such as . Innovation financial statements analysis is a perfect complement when working with Innovation Pharmaceuticals Valuation or Volatility modules.
Innovation |
Innovation Pharmaceuticals Company Operating Margin Analysis
Innovation Pharmaceuticals' Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Current Innovation Pharmaceuticals Operating Margin | (339.83) % |
Most of Innovation Pharmaceuticals' fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Innovation Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
| Competition |
Based on the recorded statements, Innovation Pharmaceuticals has an Operating Margin of -339.8333%. This is much higher than that of the Biotechnology sector and 203.23% higher than that of the Health Care industry. The operating margin for all United States stocks is notably higher than that of the company.
Innovation Pharmaceuticals Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Innovation Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Innovation Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Innovation Pharmaceuticals competition to find correlations between indicators driving Innovation Pharmaceuticals's intrinsic value. More Info.Innovation Pharmaceuticals is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Innovation Pharmaceuticals by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Innovation Pharmaceuticals' Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.About Innovation Pharmaceuticals Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Innovation Pharmaceuticals income statement, its balance sheet, and the statement of cash flows. Innovation Pharmaceuticals investors use historical funamental indicators, such as Innovation Pharmaceuticals's revenue or net income, to determine how well the company is positioned to perform in the future. Although Innovation Pharmaceuticals investors may use each financial statement separately, they are all related. The changes in Innovation Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Innovation Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Innovation Pharmaceuticals Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Innovation Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Innovation Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops small molecule therapies to treat inflammatory diseases, cancer, dermatology, and anti- infective. Innovation Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Wakefield, Massachusetts. Innovation Pharmaceuticals operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 4 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Innovation Pink Sheet Analysis
When running Innovation Pharmaceuticals' price analysis, check to measure Innovation Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Innovation Pharmaceuticals is operating at the current time. Most of Innovation Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Innovation Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Innovation Pharmaceuticals' price. Additionally, you may evaluate how the addition of Innovation Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.